For example, asciminib, a BCR-ABL inhibitor with a novel mode of action, was granted US Food and Drug Administration (FDA) approval in October 2021 for patients with Philadelphia chromosome-positive CML in chronic phase and for adult patients with Philadelphia chromosome-positive CML in chronic phase with the T315I mutation [23]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.